Novatim Immune Therapeutics

Focus: Novatim Immune Therapeutics is a China-based biotechnology company focused on cancer immunotherapy, particularly CAR-T cell therapies and bispecific antibodies for oncology and cell therapy applications.

Oncology Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Novatim Immune Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Novatim Immune Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）

Acute Lymphoblastic Leukemia, in Relapse

Phase 1

Clinical Trials (1)

NCT06445803CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Phase 1

Help build intelligence for Novatim Immune Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge CAR-T and bispecific antibody platforms in high-growth oncology segment with multiple Phase 1/2 programs advancing
Opportunity to contribute to cell therapy innovation in an emerging biotech with focus on hematologic and solid tumor malignancies
Position at early-stage company with potential for equity upside and direct impact on pipeline advancement

Watch Out For

Company has zero active job openings, suggesting minimal current hiring and potential organizational constraints
Pre-clinical/early-stage pipeline with no Phase 3 programs or marketed products creates execution risk and delayed revenue generation
Limited public financial visibility and undisclosed funding/employee count raises concerns about company stability and growth runway

Generated by Claude from Novatim Immune Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

KY-0118

Neoplasms

Phase 1

Clinical Trials (1)

NCT06175780Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

KQ-2003 CAR T-cells

POEMS Syndrome

Phase 1

Clinical Trials (1)

NCT06518876A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome

Phase 1